Liu, Junkai published the artcileIdentification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridonin, Quality Control of 118-90-1, the publication is European Journal of Medicinal Chemistry (2022), 114155, database is CAplus and MEDLINE.
The natural product oridonin has the potential to be a broad-spectrum antineoplastic agent. To develop oridonin analogs with high potency, a series of novel oridonin analogs were designed and synthesized by removing the multiple hydroxyl groups of parent compound The representative analogs 14, 19, and 26 (I – III, resp.) exhibited potent anticancer effects against K562, MDA-MB-231, SMMC-7721, and MCF-7 cells. Further structural modification on their 14-OH generated more potent derivatives 16n, 21d, and 28d, resp. (IV – VI, resp.), in which the IC50 value of compound 16n was 50-fold more potent than parent oridonin in K562 cells. Furthermore, compound 16n significantly induced the cell cycle arrest of K562 cells at the G2 phase and increased the fraction of apoptotic cells. Importantly, compounds 16n, 21d, and 28d exhibited good antitumor activities in H22 allograft mice in vivo. These results suggest that compounds 16n, 21d, and 28d deserve further development as promising candidates for the treatment of cancers.
European Journal of Medicinal Chemistry published new progress about 118-90-1. 118-90-1 belongs to catalysis-chemistry, auxiliary class Carboxylic acid,Benzene,Natural product, name is 2-Methylbenzoic acid, and the molecular formula is C8H8O2, Quality Control of 118-90-1.
Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia